despite the development in chemotherapy targeted radiotherapy and surgery the estimated survival of HNSCC remains approximately 50%.

For second line treatment options for patients refractory to platinum based chemotherapy cetuximab/taxanes/methotrexate has become the standard therapy with recurrent and or metastatic local disease,resulting in progression free survival of only 2-3 months with a response rate of 4-14%.

for patients who develop unresectable or metastatic recurrence systemic therapy depends upon platinum sensitivity as well as biological factord such as PDL1 receptor status .Sytemic therapy includes platinum based chemotherapy combination with or without Immune check point inhibitors.

Tumour cells assume particular characteristics that allow them to evade the immune system by activating co-inhibitory pathways ,thereby inducing immune tolerance and tumour progression 

the use of anti-PD-1/PD-L1 has shown to restore T-cell mediated anti-tumour immunity

Pembrolimuzumab and Nivolumabv have been approved for patients with metastatic,recurrent and unresectable HNSCC 

We evaluate the OVERALL RESPONSE RATE,DURATION OF RESPONSE AND PROGRESSION FREE SURVIVAL using PET-CT Scan of patients who are undergoing Immunotherapy